Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
作者信息
Brunner Hermine I, Schulert Grant S, Sproles Alyssa, Thornton Sherry, Cornejo Gabriel Vega, Antón Jordi, Cuttica Ruben, Henrickson Michael, Foeldvari Ivan, Kingsbury Daniel J, Askelson Margarita, Liu Jinqi, Mukherjee Sumanta, Wong Robert L, Lovell Daniel J, Martini Alberto, Ruperto Nicolino, Grom Alexei A
机构信息
Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Hospital México Americano, Guadalajara, CREA, Mexico.
出版信息
Arthritis Res Ther. 2024 Aug 31;26(1):154. doi: 10.1186/s13075-024-03385-8.
Abstract
摘要
相似文献
1
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.更正：S100蛋白作为多关节型幼年特发性关节炎中阿巴西普反应的潜在预测生物标志物。
Arthritis Res Ther. 2024 Aug 31;26(1):154. doi: 10.1186/s13075-024-03385-8.
2
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.S100 蛋白作为阿巴西普治疗多发性幼年特发性关节炎反应的潜在预测性生物标志物。
Arthritis Res Ther. 2024 Jun 25;26(1):125. doi: 10.1186/s13075-024-03347-0.
3
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.皮下注射阿巴西普治疗多关节病程幼年特发性关节炎患者：III 期开放标签研究结果。
Arthritis Rheumatol. 2018 Jul;70(7):1144-1154. doi: 10.1002/art.40466. Epub 2018 May 20.
4
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.静脉注射阿巴西普治疗日本多关节型幼年特发性关节炎患者的 III 期开放标签研究结果。
Pediatr Rheumatol Online J. 2019 Apr 30;17(1):17. doi: 10.1186/s12969-019-0319-4.
5
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.接受阿巴西普治疗的多关节病程幼年特发性关节炎患者的个体临床缓解的长期维持。
Arthritis Care Res (Hoboken). 2023 Nov;75(11):2259-2266. doi: 10.1002/acr.25156. Epub 2023 Jun 22.
6
Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.基于模型的选择和推荐：皮下注射阿巴西普剂量用于多关节型幼年特发性关节炎患者。
J Clin Pharmacol. 2021 May;61(5):688-699. doi: 10.1002/jcph.1797. Epub 2021 Jan 18.
7
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.阿巴西普：治疗多关节病程型幼年特发性关节炎的研究进展。
Paediatr Drugs. 2020 Dec;22(6):653-672. doi: 10.1007/s40272-020-00422-2. Epub 2020 Oct 8.
8
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.皮下注射阿巴西普治疗 2-5 岁多关节型幼年特发性关节炎患者对白喉/破伤风疫苗抗体应答的维持。
Pediatr Rheumatol Online J. 2020 Feb 22;18(1):19. doi: 10.1186/s12969-020-0410-x.
9
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.血清 S100A8/A9 和 S100A12 水平在儿童多关节型幼年特发性关节炎中的变化：与抗 TNF 治疗期间临床缓解疾病的维持和治疗停药后疾病复发的关系。
Arthritis Rheumatol. 2019 Mar;71(3):451-459. doi: 10.1002/art.40727. Epub 2019 Jan 24.
10
Prior to extension, Transcriptomes of fibroblast-like Synoviocytes from extended and Polyarticular juvenile idiopathic arthritis are indistinguishable.在伸展之前，来自伸展型和多关节型幼年特发性关节炎的成纤维细胞样滑膜细胞的转录组是无法区分的。
Pediatr Rheumatol Online J. 2018 Jan 8;16(1):3. doi: 10.1186/s12969-017-0217-6.
引用本文的文献
1
Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review.青少年特发性关节炎生物治疗的最新进展：一项为期五年的叙述性综述
Biologics. 2025 Jul 23;19:425-441. doi: 10.2147/BTT.S486359. eCollection 2025.
本文引用的文献
1
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.S100 蛋白作为阿巴西普治疗多发性幼年特发性关节炎反应的潜在预测性生物标志物。
Arthritis Res Ther. 2024 Jun 25;26(1):125. doi: 10.1186/s13075-024-03347-0.
Zotero 插件